{"id":"early-glargine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glargine is a recombinant human insulin analog engineered with amino acid substitutions to delay absorption and extend duration of action to approximately 24 hours. It binds to the human insulin receptor with similar affinity to endogenous insulin, activating downstream signaling that increases glucose uptake in muscle and adipose tissue while suppressing hepatic glucose production. The extended half-life allows once-daily dosing for basal insulin replacement in diabetes management.","oneSentence":"Early Glargine is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:36:01.099Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT06007508","phase":"PHASE2","title":"Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis","status":"TERMINATED","sponsor":"HealthPartners Institute","startDate":"2022-05-31","conditions":"DKA","enrollment":8},{"nctId":"NCT04567225","phase":"PHASE4","title":"Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-10-01","conditions":"Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes","enrollment":39},{"nctId":"NCT03107208","phase":"PHASE4","title":"Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-07-21","conditions":"Diabetic Ketoacidosis, Type 1 Diabetes Mellitus","enrollment":61},{"nctId":"NCT02930044","phase":"NA","title":"Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2016-10","conditions":"Diabetic Ketoacidosis","enrollment":18},{"nctId":"NCT03670641","phase":"PHASE4","title":"Remission Through Early Monitored Insulin Therapy - Duration Month","status":"COMPLETED","sponsor":"Sandra Sobel","startDate":"2019-03-26","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT04383990","phase":"NA","title":"Early Versus Late Administration of Insulin Glargine in T1DM During Fasting Ramadan","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2020-02-28","conditions":"Type1diabetes, Fasting, Insulin","enrollment":185},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT03687827","phase":"PHASE4","title":"A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":498},{"nctId":"NCT02192424","phase":"PHASE3","title":"Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":109},{"nctId":"NCT02548494","phase":"NA","title":"Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes","status":"TERMINATED","sponsor":"Chattanooga-Hamilton County Hospital Authority","startDate":"2015-11","conditions":"Diabetes Mellitus, Type 1, Diabetic Ketoacidosis","enrollment":17},{"nctId":"NCT00505882","phase":"PHASE4","title":"Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-07","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT01755468","phase":"PHASE3","title":"Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT00179127","phase":"NA","title":"Use of Insulin Glargine to Treat Diabetic Ketoacidosis","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2004-08","conditions":"Diabetic Ketoacidosis","enrollment":75},{"nctId":"NCT00970528","phase":"PHASE4","title":"Glucose Reduction by Early Acarbose Treatment in Basal Insulin","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":124},{"nctId":"NCT00069784","phase":"PHASE3","title":"The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-08","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":12537},{"nctId":"NCT00857870","phase":"PHASE4","title":"Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2009-03","conditions":"Type 2 Diabetes","enrollment":96},{"nctId":"NCT00366301","phase":"PHASE4","title":"The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2006-08","conditions":"Type 2 Diabetes","enrollment":500},{"nctId":"NCT00347100","phase":"PHASE4","title":"Insulin Glargine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Diabetes Mellitus, Type 2","enrollment":387}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lantus"],"phase":"marketed","status":"active","brandName":"Early Glargine","genericName":"Early Glargine","companyName":"The Cleveland Clinic","companyId":"the-cleveland-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Early Glargine is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}